Osteosarcoma cells depend on MCL-1 for survival, and osteosarcoma metastases respond to MCL-1 antagonism plus regorafenib in vivo.

Autor: Ji, Yanhao¹ (AUTHOR), Harris, Michael A.^1,2 (AUTHOR), Newton, Lucas M.^1,3 (AUTHOR), Harris, Tiffany J.⁴ (AUTHOR), Fairlie, W. Douglas^1,4,5 (AUTHOR), Lee, Erinna F.^1,4,5 (AUTHOR), Hawkins, Christine J.^1,2 (AUTHOR) c.hawkins@latrobe.edu.au

Publikováno v: BMC Cancer. 11/4/2024, Vol. 24 Issue 1, p1-14. 14p.

MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation

Autor: Baranski, Z., Booij, T.H., Kuijjer, M.L., Jong, Y. de, Cleton-Jansen, A.M., Price, L.S., Water, B. van de, Bovée, J.V., Hogendoorn, P.C., Danen, E.H.

Conventional high-grade osteosarcoma is the most common primary bone cancer with relatively high incidence in young people. Recurrent and metastatic tumors are difficult to treat. We performed a kinase inhibitor screen in two osteosarcoma cell lines,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::ba35342eacee4e529c02041c380c8eea
https://hdl.handle.net/1887/3197459

Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma.

Autor: Venneker S; Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Kruisselbrink AB; Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Baranski Z; Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands., Palubeckaite I; Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Briaire-de Bruijn IH; Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Oosting J; Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., French PJ; Department of Neurology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., Danen EHJ; Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands., Bovée JVMG; Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

Publikováno v: Cancers [Cancers (Basel)] 2020 Nov 30; Vol. 12 (12). Date of Electronic Publication: 2020 Nov 30.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A screening-based approach identifies cell cycle regulators AURKA, CHK1 and PLK1 as targetable regulators of chondrosarcoma cell survival.

Autor: de Jong Y; Department of Pathology, Leiden University Medical Centre, P.O. Box 9600, L1-Q, 2300 RC Leiden, the Netherlands., Bennani F; Department of Pathology, Leiden University Medical Centre, P.O. Box 9600, L1-Q, 2300 RC Leiden, the Netherlands., van Oosterwijk JG; Department of Pathology, Leiden University Medical Centre, P.O. Box 9600, L1-Q, 2300 RC Leiden, the Netherlands., Alberti G; Department of Pathology, Leiden University Medical Centre, P.O. Box 9600, L1-Q, 2300 RC Leiden, the Netherlands., Baranski Z; Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, P.O. Box 9502, 2300 RA Leiden, the Netherlands., Wijers-Koster P; Department of Pathology, Leiden University Medical Centre, P.O. Box 9600, L1-Q, 2300 RC Leiden, the Netherlands., Venneker S; Department of Pathology, Leiden University Medical Centre, P.O. Box 9600, L1-Q, 2300 RC Leiden, the Netherlands., Briaire-de Bruij IH; Department of Pathology, Leiden University Medical Centre, P.O. Box 9600, L1-Q, 2300 RC Leiden, the Netherlands., van de Akker BE; Department of Pathology, Leiden University Medical Centre, P.O. Box 9600, L1-Q, 2300 RC Leiden, the Netherlands., Baelde H; Department of Pathology, Leiden University Medical Centre, P.O. Box 9600, L1-Q, 2300 RC Leiden, the Netherlands., Cleton-Jansen AM; Department of Pathology, Leiden University Medical Centre, P.O. Box 9600, L1-Q, 2300 RC Leiden, the Netherlands., van de Water B; Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, P.O. Box 9502, 2300 RA Leiden, the Netherlands., Danen EHJ; Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, P.O. Box 9502, 2300 RA Leiden, the Netherlands., Bovée JVMG; Department of Pathology, Leiden University Medical Centre, P.O. Box 9600, L1-Q, 2300 RC Leiden, the Netherlands.

Publikováno v: Journal of bone oncology [J Bone Oncol] 2019 Nov 17; Vol. 19, pp. 100268. Date of Electronic Publication: 2019 Nov 17 (Print Publication: 2019).